PolyPid (PYPD) announced a new research and development collaboration with ImmunoGenesis, a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel formulations utilizing PolyPid’s experience with its proprietary PLEX Technology and ImmunoGenesis’ potent STimulator of INterferon Genes, STING, agonist drug candidate to potentially enhance treatment for solid tumors.
Education
About Us
Working with TipRanks
Follow Us
1